Correction to Lancet Neurol 2021; 20: 1012–16 (The Lancet Neurology (2021) 20(12) (1012–1026), (S1474442221002416), (10.1016/S1474-4422(21)00241-6))

摘要

? 2022 Elsevier LtdDiaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol 2021; 20: 1012–16—In this Article, the value for upper extremity weakness on the Pompe disease symptom scale in figure 3 has been corrected to no longer favour alglucosidase alfa. These corrections have been made to the online version as of March 16, 2022.